Table 4 Vaccine trials including checkpoint inhibitor mABs
From: A quantitative analysis of therapeutic cancer vaccines in phase 2 or phase 3 trial
NCT Number | Title | Indication | Sponsor/Collaborators | Phases | Vaccine Type | Vaccine Name | MAB |
|---|---|---|---|---|---|---|---|
NCT00077532 (completed) | Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma | Melanoma | National Institutes of Health Clinical Center (CC) National Cancer Institute (NCI) | Phase 2 | Peptide-based vaccine (adjuvanted) | gp100 antigen in incomplete Freund’s adjuvant | Ipilimumab |
NCT00094653 (completed) | MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma | Melanoma | Bristol-Myers Squibb | Phase 3 | Peptide-based vaccine (multi-peptide) | MDX-1379 (gp100) Melanoma Peptide Vaccine | Ipilimumab |
NCT00084656 (completed) | Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma | Melanoma | Bristol-Myers Squibb National Cancer Institute (NCI) | Phase 2 | Peptide-based vaccine (multi-peptide, adjuvanted) | Tyrosinase/gp100/MART-1 Peptide vaccine in Montanide | Ipilimumab |
NCT01067287 (ongoing) | Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation | Myeloma | Beth Israel Deaconess Medical Center Dana-Farber Cancer Institute Brigham and Women's Hospital Rambam Health Care Campus Gateway for Cancer Research Department of Defense | Phase 2 | Dendritic cell-based vaccine (autologous tumour-fused) | Dendritic Cell/Myeloma Fusion Cell Vaccine with or without CT-011 | Pidilizumab (CT-011) |
NCT02054520 (ongoing) | Immunotherapy Study for Patients With Stage IV Melanoma | Melanoma | NewLink Genetics Corporation | Phase 2 | Tumour cell-based vaccine (allogenic, aGal transfected) | Hyperacute Melanoma Cancer vaccine Dorgenmeltucel-L | Ipilimumab |
NCT01096602 (ongoing) | Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission | Leukemia | Beth Israel Deaconess Medical Center National Institutes of Health (NIH) CureTech Ltd Dana-Farber Cancer Institute | Phase 2 | Dendritic cell-based vaccine (autologous tumour-fused) | Dendritic Cell/AML Fusion Cell Vaccine with or without CT-011 | Pidilizumab (CT-011) |
NCT01441765 (ongoing) | PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine | Renal Cell Cancer (RCC) | Beth Israel Deaconess Medical Center National Institutes of Health (NIH) National Cancer Institute (NCI) Dana-Farber Cancer Institute | Phase 2 | Dendritic cell-based vaccine (autologous tumour-fused) | Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine with or without CT-011 | Pidilizumab (CT-011) |
NCT01420965 (ongoing) | Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer | Neoplasm | Georgia Regents University | Phase 2 | Dendritic cell-based vaccine (autologous tumour-pulsed) | Provenge (Sipuleucel-T/APC8015) + Drug: CT-011 (Anti-PD1 Antibody) | Pidilizumab (CT-011) |
NCT01896869 (ongoing) | A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab With Allogenic GM-CSF Transfected Pancreatic Tumor Vaccine in the Treatment of Metastatic Pancreatic Cancer | Pancreatic Cancer | Sidney Kimmel Comprehensive Cancer Center | Phase 2 | Tumour cell-based vaccine (allogenic, GM-CSF transfected) | GVAX | Ipilimumab |
NCT02243371 (ongoing) | GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab | Pancreatic Cancer | Sidney Kimmel Comprehensive Cancer Center Bristol-Myers Squibb Stand Up To Cancer Aduro BioTech AACR Research Acceleration Network | Phase 2 | Tumour cell-based vaccine (allogenic, GM-CSF transfected), Bacteria-based vaccine (Listeria) | GVAX | nivolumab |
NCT00032045 (completed) | Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma | Melanoma | National Cancer Institute (NCI) | Phase 2 | Peptide-based vaccine (adjuvanted) | gp100 antigen incomplete Freund’s adjuvant | Ipilimumab |
NCT00357461 (withdrawn prior to enrolment) | Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma | Melanoma | Bristol-Myers Squibb National Cancer Institute (NCI) | Phase 2 | Peptide-based vaccine (multi-peptide, adjuvanted) | gp100:209-217(210M) & gp100:280-288(288V) peptide vaccine in incomplete Freund’s adjuvant | Ipilimumab |